ClinicalTrials.gg
RecruitingNCT05555017Trace-IIUpdated Oct 6, 2023

Tracer-Guided Surgery for Recurrent Prostate Cancer

A Phase 2 interventional study of PSMA-radioguided surgery and ADT in Prostate Cancer, sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by The Netherlands Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute — 6 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · The Netherlands Cancer Institute.

Planned enrollment
5th of 13
60 · median 54
Started
2023
with 2 others
Phase 2
2 of 16
1 open now
Registered
10th of 16
by date

Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, or all of them as a file.
02

Study summary

ADT with or without robot-assisted PSMA-radioguided surgery for patients with recurrent prostate cancer.

Read the detailed description

Improving the oncological treatment outcomes in men with a biochemical recurrence after primary prostate cancer (PC) treatment that are diagnosed with a disease recurrence confined to the regional lymph nodes or local residual disease using Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography and Computed Tomography (PET/CT.)

The proposed trial randomizes patients with recurrent PC following primary PC treatment to either 6 months of ADT or Technetium-PSMA-radioguided salvage surgery plus 6 months of ADT. Although the optimal duration of ADT is unknown, a minimal duration of 6 months of ADT seems advisable in this setting and will be mandatory for both arms.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • PSMA-radioguided surgery
  • ADT
  • recurrent prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged ≥ 18 years.
  • Hormone-sensitive recurrent prostate cancer after radical prostatectomy, external beam radiotherapy or brachytherapy
  • ≤ 2 lymph node or local residual disease within the pelvis with sufficient PSMA expression (≥2 times regional vascular activity level) as determined by PSMA-based PET
  • PSA-value \< 4 ng/mL in case of a local recurrence and PSA \< 3 ng/ml in case of (a) nodal recurrence(s)
  • Had a PSMA PET/CT within 90 days before surgery
  • Suitable for salvage surgery, as per institutional guidelines.
  • Charlson Comorbidity Index ≤ 4
  • World Health Organisation (WHO) performance status 0, 1, or 2.
  • Written and signed .

Exclusion criteria

Exclusion Criteria:

  • Other diagnosis of or evidence of other malignancy within 5 years before screening for this study (except non-melanoma skin cancer).
  • More than 2 lymph node on PSMA PET/CT
  • Suspicion of local recurrent prostate cancer within the prostatic fossa not treatable by surgery
  • Non-regional lymphadenopathy (cM1a) or distant metastases (cM1b/c) as assessed by preoperative PSMA PET/CT.
  • Castration resistance defined by clinical or biochemical progression despite a combined androgen blockade
  • Known to hormone therapy, according to standard recommendations in force
  • Patient with a psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule
  • Ongoing androgen deprivation therapy (ADT) or within 6 months prior to surgery.
  • Severe claustrophobia interfering with PET/CT scanning.
  • Absence or withdrawal of an
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Arm A: ADT

    Patients in arm A will receive standard 6 months of ADT according to current clinical guidelines.

    Drug: ADT

  • Experimental
    Arm B: ADT + PSMA radioguided surgery

    Patients in arm B will receive standard 6 months of ADT according to current clinical guidelines, and will undergo 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery.

    Procedure: PSMA-radioguided surgery · Drug: ADT

Interventions

  • ProcedurePSMA-radioguided surgery

    Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.

06

What researchers measure

Primary outcomes

  1. Clinical progression-free survival (CPFS)

    CPFS is defined as time between randomization and the appearance of a recurrence (any N1 or M1) as suggested by PSMA PET/CT or symptoms related to progressive PC, or death due to any cause

    Time frame: 24 months

Secondary outcomes

  1. Metastasis-free survival (MFS)

    Metastasis-free survival will be defined as the time between randomization and the appearance of a metastatic recurrence (any M1) as suggested by PSMA PET-CT.

    Time frame: 24 months

  2. Biochemical progression-free survival (BPFS)

    Biochemical progression-free survival will be defined as the time between randomization and the development of biochemical progression ( three consecutive rises in prostate specific antigen (PSA) 1 week apart, resulting in two 50% increases over the nadir and PSA\>2 ng/ml)

    Time frame: 24 months

  3. Castrate resistant prostate cancer (CRPC)

    CRPC is defined as castrate serum testosterone\<50 ng/dl plus biochemical progression, i.e., three consecutive rises in PSA 1 week apart, resulting in two 50% increases over the nadir and PSA\>2 ng/ml.

    Time frame: 10 years

  4. Overall survival (OS)

    Overall survival will be read as the time from trial randomization to the date of death from any cause

    Time frame: 10 years

  5. Incidence of adjuvant therapy

    ADT, radiation therapy or additional salvage surgery

    Time frame: 10 years

  6. Patient reported QOL as per EORTC-QLQ C30

    Quality of life (QoL) will be assessed with the EORTC Core Quality of Life questionnaire's (QLQ-C30) global QoL scale ranging from 0 to 100, higher scores indicate better QoL

    Time frame: 24 months

  7. Patient reported QOL as per Expanded Prostate cancer Index Composite (EPIC) 26

    Quality of life (QoL) will be assessed with the EPIC 26 questionnaire, containing 26 items covering 5 domains: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better QOL.

    Time frame: 24 months

  8. Complications

    Assessment of 99mTc-PSMA-I\&S injection-related as well as surgery-related complication rate according to Clavien-Dindo.

    Time frame: 30 and 90 days

  9. Number of in-field recurrences

    Recurrence measured by use of PSMA PET/CT in the template of 99mTc-PSMA-radioguided surgery (RGS) supported salvage surgery

    Time frame: 24 months

  10. Specificity of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation

    In percentage

    Time frame: 30 days

  11. Sensitivity of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation

    In percentage

    Time frame: 30 days

  12. Positive Predictive Value of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation

    In percentage

    Time frame: 30 days

  13. Negative Predictive Value of 99mTc-PSMA RGS for salvage surgery for recurrent PC compared to histologic evaluation

    In percentage

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Nov 2024, 21 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 21 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Sep 26, 2022
StartActual
Feb 15, 2023
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2025
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05555017
Responsible party
Sponsor
First posted
Sep 26, 2022
Start date
Feb 15, 2023
Primary completion
Nov 2024 (estimated)
Completion
Nov 2025 (estimated)
Last update
Oct 6, 2023

Study contacts

Pim van Leeuwen, MD, PhD
Contact
pj.v.leeuwen@nki.nl
003125129111
Lotte Zuur, MD
Contact
l.zuur@nki.nl
003125129111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion